Navigating the FDA's guidance on real-world evidence (RWE) for expanded access

Navigating the FDA's evolving landscape regarding real-world evidence (RWE) is essential for sponsors seeking to utilize expanded access mechanisms for unmet medical needs. As regulatory frameworks increasingly integrate post-marketing data to inform labeling decisions, understanding how RWE interacts with emergency use or compassionate use programs becomes a critical competency for modern drug developers.

The Intersection of RWE and Expanded Access

Expanded access, often referred to as compassionate use, traditionally allows patients with life-threatening conditions to access investigational drugs before they are approved for widespread use. Historically, the pathway to expanded access relied heavily on clinical trial data generated under controlled conditions. However, the FDA has begun to recognize that data generated outside of controlled trials can provide valuable insights into a drug's safety and efficacy in real-world settings. This shift means that sponsors must now consider how to generate, curate, and submit RWE to support or inform expanded access requests.

Strategic Considerations for Data Generation

When designing a strategy to incorporate RWE into an expanded access application, sponsors must align their data collection methods with FDA expectations. The goal is not merely to gather data but to ensure it is robust, credible, and directly relevant to the specific patient population accessing the drug. This requires a clear understanding of what the FDA considers "real-world" in the context of a specific therapeutic area and disease state.

  1. Define the Population: Clearly delineate the patient subgroup accessing the drug based on real-world criteria rather than strict inclusion/exclusion protocols used in Phase I or II trials.
  2. Outcome Selection: Identify clinical endpoints that are meaningful to patients and clinicians, such as quality-of-life measures or functional status improvements, rather than solely relying on surrogate markers.
  3. Data Integrity: Ensure the data collection process adheres to Good Clinical Practice (GCP) principles as closely as possible, even when operating outside a formal clinical trial site.

Utilizing Existing Databases and Registries

One of the most efficient ways to generate RWE for expanded access purposes is leveraging existing data sources. The FDA encourages the use of established databases, registries, and health information exchanges that have been validated for the intended purpose. These sources can provide a historical baseline or comparative data that helps contextualize the new expanded access patient population.

  • National Cancer Database (NCD): Useful for oncology applications to contextualize survival rates and treatment patterns.
  • EHR Systems: Electronic Health Records can offer longitudinal data on treatment outcomes if linked with proper anonymization protocols.
  • Disease-Specific Registries: Dedicated registries for rare diseases or specific conditions often contain high-quality, pre-collected data relevant to the target population.

Submitting RWE: The Science and Evidence Content Format

Once data is collected or sourced, the challenge lies in presenting it effectively within the expanded access submission. The FDA has released the Science and Evidence Content Format (SEC Form) specifically to streamline the submission of RWE. This form provides a structured approach to organizing the data, ensuring that reviewers can quickly assess the relevance and quality of the evidence. Sponsors must map their collected data to the specific sections of the SEC Form, highlighting how the RWE supports the safety and efficacy claims necessary for expanded access.

Validating and Contextualizing the Evidence

The core of a successful RWE submission is the ability to contextualize the findings. Simply presenting raw data is insufficient; sponsors must demonstrate how the RWE relates to the known clinical trial data. This often involves conducting a comparative analysis to show consistency or, if necessary, explaining deviations between trial results and real-world observations. The submission must address potential biases inherent in observational data, such as selection bias or confounding factors, and propose methods to mitigate these issues. By providing a transparent and rigorous analysis, sponsors can build a compelling case that the RWE is sufficient to inform regulatory decisions regarding expanded access.

Future Implications for Drug Development

The integration of RWE into expanded access strategies represents a significant evolution in how the FDA views post-marketing and pre-marketing data utility. As more guidance documents are issued and precedents are set through various advisory committee meetings, the role of RWE will likely expand beyond expanded access to include label expansion and risk management planning. For pharmaceutical companies, staying ahead of these developments is crucial. Proactive engagement with the FDA, whether through pre-submission meetings or advisory forums, can help clarify expectations and foster a collaborative environment for bringing life-saving treatments to patients who lack other options. Ultimately, mastering the navigation of RWE requirements ensures that expanded access programs remain effective, compliant, and impactful for the patients they serve.

Related reading